Barry Quart
Chief Executive Officer Connect Biopharmaceuticals
Seminars
Tuesday 15th September 2026
Repositioning Rapid Acting IL‑4Rα Biologics for Acute Exacerbations in Asthma & COPD: A Dual‑Phase Approach to Rapid Lung Function Recovery & Inflammatory Control
9:30 am
- Examine how IL‑4/IL‑13 pathway blockade via rapidly acting IL‑4Rα biologics can be repositioned for acute intervention, addressing not only inflammation but the IL‑13–driven mechanical constraints that limit bronchodilator responsiveness during active exacerbations
- Understand how rapid suppression of IL‑4/IL-13 signaling permits early recovery of airway function (minutes to hours) by relieving bronchomotor tone and initiating time‑dependent cytoskeletal softening, resulting in clinically meaningful improvements in FEV₁
- Explore a dual‑phase treatment paradigm in which early functional recovery is followed by sustained inflammatory control, bridging immediate symptom relief with downstream disease modification during and after exacerbations
